Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
23.08
-1.80 (-7.23%)
At close: Feb 27, 2026, 4:00 PM EST
23.10
+0.02 (0.09%)
After-hours: Feb 27, 2026, 7:57 PM EST
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Catalyst Pharmaceuticals stock have an average target of 32.5, with a low estimate of 32 and a high estimate of 33. The average target predicts an increase of 40.81% from the current stock price of 23.08.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Catalyst Pharmaceuticals stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 1 |
| Buy | 4 | 4 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 6 | 6 | 6 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +42.98% | Nov 7, 2025 |
| Baird | Baird | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +38.65% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +51.65% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $33 | Buy | Reiterates | $33 | +42.98% | Feb 27, 2025 |
| Baird | Baird | Buy Initiates $28 | Buy | Initiates | $28 | +21.32% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
631.03M
from 588.99M
Increased by 7.14%
Revenue Next Year
679.48M
from 631.03M
Increased by 7.68%
EPS This Year
1.82
from 1.68
Increased by 8.07%
EPS Next Year
1.87
from 1.82
Increased by 2.81%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 665.4M | 755.2M | |||
| Avg | 631.0M | 679.5M | |||
| Low | 583.6M | 624.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 13.0% | 19.7% | |||
| Avg | 7.1% | 7.7% | |||
| Low | -0.9% | -1.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 2.07 | 2.19 | ||
| Avg | 1.82 | 1.87 | ||
| Low | 1.51 | 1.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 23.1% | 20.9% | ||
| Avg | 8.1% | 2.8% | ||
| Low | -10.2% | -10.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.